Skip to main content
Fig. 4 | Cost Effectiveness and Resource Allocation

Fig. 4

From: A budget impact analysis of substituting sitagliptin with liraglutide in type 2 diabetes from a private health insurance perspective in Egypt

Fig. 4

One-way sensitivity analysis results for liraglutide. GLP1-RA Glucagon like peptide 1 receptor agonist, SGLT2i Sodium/glucose cotransporter-2 inhibitors, TZD thiazolidinediones, HF heart failure, CABG Coronary artery bypass graft. The light grey bar corresponds with the upper range, and the dark blue bar with the lower range of an input

Back to article page